ClinicalTrials.gg
CompletedNCT00027027Updated Jul 27, 2015Results posted

Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors

A Phase 1 interventional study of rhuMAb 2C4 in Neoplasms, sponsored by Genentech, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-27.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this Phase I study is to test the safety of rhuMAb 2C4 to see what effects (good and bad) it has on patients with certain types of cancer, and also to find the highest dose of rhuMAb that can be given without causing severe side effects. All study participants will be assigned to specific group to evaluate different dosages of rhuMAb 2C4. The study is scheduled to run for up to one year depending on how patients respond to the study treatment.

02

Conditions studied

  • Neoplasms

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 21 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Age >=18 years old
  • performance status of 0 or 1 (see Appendix F)
  • of >=12 weeks
  • documented, incurable, locally advanced or solid
  • Disease progression on or after standard effective therapy or a malignancy for which there is no standard therapy
  • At least one bi-dimensionally (>=2 cm [>=1 cm on spiral CT scan])
  • -negative status as defined by fluorescence in situ hybridization (FISH) testing (only for subjects with breast cancer)
  • Use of an effective means of for women of
  • Granulocyte count of >=1500/uL, count of >=100,000/uL, and of >=9 g/dL
  • Serum less than or equal to the (ULN) and alkaline phosphatase, , and ALT \<=2.5x ULN (ALT and AST \<=5x ULN for subjects with liver metastases; alkaline phosphatase \<=5x ULN for subjects with liver or bone metastases)
  • Serum creatinine less than or equal to ULN or of >=60 mL/min
  • (INR) of \<1.3 and activated partial thromboplastin time (aPTT) of \<1.5x ULN

Exclusion criteria

Exclusion Criteria:

  • Pleural effusions, ascites, or bone lesions as the only manifestation of the current cancer
  • Symptomatic or untreated
  • Prior chemotherapy, hormonal therapy (except for androgen-deprivation therapy for subjects with prostate cancer), radiotherapy, or immunotherapy within 4 weeks of Day 1 (within 6 weeks for nitrosoureas or mitomycin)
  • Prior treatment with Herceptin
  • Prior cumulative doxorubicin dose of >360 mg/m2 or the equivalent
  • History of other within 5 years of Day 1 except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer
  • History of significant cardiac disease, unstable angina, congestive heart failure, myocardial infarction, or ventricular arrhythmia requiring medication
  • of \<50% or below the lower limit of normal determined by ECHO (Subjects who are unable to have ejection fraction evaluated by ECHO may have ejection fraction evaluated by a MUGA scan, although this must be discussed with the Medical Monitor prior to enrollment.)
  • Active infection requiring IV antibiotics
  • Uncontrolled hypercalcemia (>11.5 mg/dL)
  • history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
  • Known (HIV) infection
  • Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an drug or that may affect the interpretation of the results or render the subject at high risk from treatment complications
  • Major surgery or significant traumatic injury within 3 weeks of Day 1
  • Pregnancy or lactation
  • Inability to comply with study and follow-up procedures
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With an Adverse Event (AE), Serious Adverse Event (SAE), or Death

    For this protocol, an AE is defined any untoward medical occurrence (e.g., sign, symptom, disease, syndrome, intercurrent illness, abnormal laboratory finding) that emerges or worsens relative to pretreatment baseline during the treatment or post-treatment periods, regardless of the suspected cause. For this protocol an SAE was defined as any AE that occurred at any dose if: * It resulted in death (i.e., the AE caused or led to death), * It was life threatening, * It required or prolonged inpatient hospitalization, * It was disabling, * It resulted in a congenital anomaly/birth defect, * It may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the outcomes listed above. The primary cause of death for all reported cases was disease progression, and all of the deaths occurred following study discontinuation, with one death occurring within 4 weeks of the last treatment day.

    Time frame: Days 1, 2, 5, 8, and 15 of Cycle 1; Days 1, 8, and Week 3, of Cycles 2 and beyond up to 1 year and at the follow-up visit (4 weeks after last infusion)

  2. Number of Participants With Dose-Limiting Toxicities (DLTs)

    Incidence of DLTs defined as any Grade 3 or 4 major organ toxicity according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) Version 2 or any subjectively intolerable toxicity felt by the investigator to be related to rhuMAb 2C4. One participant in the 15.0 mg/kg dose group experienced a gastrointestinal hemorrhage on Day 16. This event was judged by the investigator to be related to study drug. The participant recovered in 3 days and continued to receive rhuMAb 2C4 beyond Cycle 2.This was the only DLT reported during the first two treatment cycles.

    Time frame: Day 1 of Cycles 1 and 2, and 24 hours after Cycle 2 infusion

Secondary outcomes

  1. Pharmacokinetic Measurement of Area Under the Curve (AUC)

    Mean rhuMAb 2C4 serum concentrations versus nominal time profiles for the first two treatment cycles are presented for AUC micrograms per milliliters (ug/mL) by day. A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.

    Time frame: Days 1 (predose, 89 minutes following start of infusion and at 1.5, 4, and 8 hours postdose) 2, 5, 8 and 15 of Cycle 1; Days 1 (predose and 29 minutes following start of infusion) and 8 of Cycle 2

  2. Pharmacokinetic Measurement of Systemic Clearance (CL)

    A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.

    Time frame: Days 1 (predose, 89 minutes from infusion start, at 1.5, 4, and 8 hours postdose), 2, 5, 8 and 15 of Cycle 1; Days 1 (predose, 29 minutes from infusion start) and 8 of Cycles 2 and beyond until the follow-up visit (4 weeks after the last infusion)

  3. Pharmacokinetic Measurement of Volume of Central Compartment (Vc)

    A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.

    Time frame: Days 1 (predose, 89 minutes from infusion start, at 1.5, 4, and 8 hours postdose), 2, 5, 8 and 15 of Cycle 1; Days 1 (predose, 29 minutes from infusion start) and 8 of Cycles 2 and beyond until the follow-up visit (4 weeks after the last infusion)

  4. Pharmacokinetic Measurement of Steady-State Volume of Distribution (Vss)

    A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.

    Time frame: Days 1 (predose, 89 minutes from infusion start, at 1.5, 4, and 8 hours postdose), 2, 5, 8 and 15 of Cycle 1; Days 1 (predose, 29 minutes from infusion start) and 8 of Cycles 2 and beyond until the follow-up visit (4 weeks after the last infusion)

  5. Pharmacokinetic Measurement of Initial Distribution Half-Life (t1/2 Initial)

    A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.

    Time frame: Days 1 (predose, 89 minutes from infusion start, at 1.5, 4, and 8 hours postdose), 2, 5, 8 and 15 of Cycle 1; Days 1 (predose, 29 minutes from infusion start) and 8 of Cycles 2 and beyond until the follow-up visit (4 weeks after the last infusion)

  6. Pharmacokinetic Measurement of Terminal Half-Life (t1/2 Terminal) in Days

    A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.

    Time frame: Days 1 (predose, 89 minutes from infusion start, at 1.5, 4, and 8 hours postdose), 2, 5, 8 and 15 of Cycle 1; Days 1 (predose, 29 minutes from infusion start) and 8 of Cycles 2 and beyond until the follow-up visit (4 weeks after the last infusion)

07

Results

Posted Jul 27, 2015

Participant flow

Participant flow — Overall Study
MilestonerhuMAb 2C4: 0.5 Milligrams Per Kilogram (mg/kg)rhuMAb 2C4: 2 mg/kgrhuMAb 2C4: 5 mg/kgrhuMAb 2C4: 10 mg/kgrhuMAb 2C4: 15 mg/kg
Started33438
Discontinued before 2 treatment cycles00101
Completed 2 cycles of treatment33337
Discontinued at cycle 222113
Treated beyond cycle 211224
Completed00000
Not completed33438
Withdrew: Adverse event00101
Withdrew: Admitted for signs of pd00001
Withdrew: Clinical symptoms progression not pd10000
Withdrew: Pd requiring surgery00100
Withdrew: Physician decision due to pd23235
Withdrew: Withdrawal by subject00001

Outcome measures

PrimaryNumber of Participants With an Adverse Event (AE), Serious Adverse Event (SAE), or Death

For this protocol, an AE is defined any untoward medical occurrence (e.g., sign, symptom, disease, syndrome, intercurrent illness, abnormal laboratory finding) that emerges or worsens relative to pretreatment baseline during the treatment or post-treatment periods, regardless of the suspected cause. For this protocol an SAE was defined as any AE that occurred at any dose if: * It resulted in death (i.e., the AE caused or led to death), * It was life threatening, * It required or prolonged inpatient hospitalization, * It was disabling, * It resulted in a congenital anomaly/birth defect, * It may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the outcomes listed above. The primary cause of death for all reported cases was disease progression, and all of the deaths occurred following study discontinuation, with one death occurring within 4 weeks of the last treatment day.

Time frame:
Days 1, 2, 5, 8, and 15 of Cycle 1; Days 1, 8, and Week 3, of Cycles 2 and beyond up to 1 year and at the follow-up visit (4 weeks after last infusion)
Reported as:
Number · participants
Number of Participants With an Adverse Event (AE), Serious Adverse Event (SAE), or Death
participantsrhuMAb 2C4: 0.5 mg/kgrhuMAb 2C4: 2 mg/kgrhuMAb 2C4: 5 mg/kgrhuMAb 2C4: 10 mg/kgrhuMAb 2C4: 15 mg/kg
Adverse events33438
Serious adverse events31205
Death31201
PrimaryNumber of Participants With Dose-Limiting Toxicities (DLTs)

Incidence of DLTs defined as any Grade 3 or 4 major organ toxicity according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) Version 2 or any subjectively intolerable toxicity felt by the investigator to be related to rhuMAb 2C4. One participant in the 15.0 mg/kg dose group experienced a gastrointestinal hemorrhage on Day 16. This event was judged by the investigator to be related to study drug. The participant recovered in 3 days and continued to receive rhuMAb 2C4 beyond Cycle 2.This was the only DLT reported during the first two treatment cycles.

Time frame:
Day 1 of Cycles 1 and 2, and 24 hours after Cycle 2 infusion
Reported as:
Number · participants
Number of Participants With Dose-Limiting Toxicities (DLTs)
participantsrhuMAb 2C4: 0.5 mg/kgrhuMAb 2C4: 2 mg/kgrhuMAb 2C4: 5 mg/kgrhuMAb 2C4: 10 mg/kgrhuMAb 2C4: 15 mg/kg
Number of Participants With Dose-Limiting Toxicities (DLTs)31206
SecondaryPharmacokinetic Measurement of Area Under the Curve (AUC)

Mean rhuMAb 2C4 serum concentrations versus nominal time profiles for the first two treatment cycles are presented for AUC micrograms per milliliters (ug/mL) by day. A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.

Time frame:
Days 1 (predose, 89 minutes following start of infusion and at 1.5, 4, and 8 hours postdose) 2, 5, 8 and 15 of Cycle 1; Days 1 (predose and 29 minutes following start of infusion) and 8 of Cycle 2
Reported as:
Mean · ug*hr/mL
Pharmacokinetic Measurement of Area Under the Curve (AUC)
ug*hr/mLrhuMAb 2C4: 0.5 mg/kgrhuMAb 2C4: 2 mg/kgrhuMAb 2C4: 5 mg/kgrhuMAb 2C4: 10 mg/kgrhuMAb 2C4: 15 mg/kg
Pharmacokinetic Measurement of Area Under the Curve (AUC)43.057 ± 17.770569.433 ± 168.9951478.000 ± 349.3963959.333 ± 1110.1134502.625 ± 1245.289
SecondaryPharmacokinetic Measurement of Systemic Clearance (CL)

A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.

Time frame:
Days 1 (predose, 89 minutes from infusion start, at 1.5, 4, and 8 hours postdose), 2, 5, 8 and 15 of Cycle 1; Days 1 (predose, 29 minutes from infusion start) and 8 of Cycles 2 and beyond until the follow-up visit (4 weeks after the last infusion)
Reported as:
Mean · mL/day/kg
Pharmacokinetic Measurement of Systemic Clearance (CL)
mL/day/kgrhuMAb 2C4: 0.5 mg/kgrhuMAb 2C4: 2 mg/kgrhuMAb 2C4: 5 mg/kgrhuMAb 2C4: 10 mg/kgrhuMAb 2C4: 15 mg/kg
Pharmacokinetic Measurement of Systemic Clearance (CL)13.1 ± 5.53.74 ± 1.283.52 ± 0.852.69 ± 0.923.68 ± 1.47
SecondaryPharmacokinetic Measurement of Volume of Central Compartment (Vc)

A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.

Time frame:
Days 1 (predose, 89 minutes from infusion start, at 1.5, 4, and 8 hours postdose), 2, 5, 8 and 15 of Cycle 1; Days 1 (predose, 29 minutes from infusion start) and 8 of Cycles 2 and beyond until the follow-up visit (4 weeks after the last infusion)
Reported as:
Mean · mL/kg
Pharmacokinetic Measurement of Volume of Central Compartment (Vc)
mL/kgrhuMAb 2C4: 0.5 mg/kgrhuMAb 2C4: 2 mg/kgrhuMAb 2C4: 5 mg/kgrhuMAb 2C4: 10 mg/kgrhuMAb 2C4: 15 mg/kg
Pharmacokinetic Measurement of Volume of Central Compartment (Vc)43.6 ± 4.635.5 ± 3.539.7 ± 6.238.4 ± 5.342.8 ± 7.9
SecondaryPharmacokinetic Measurement of Steady-State Volume of Distribution (Vss)

A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.

Time frame:
Days 1 (predose, 89 minutes from infusion start, at 1.5, 4, and 8 hours postdose), 2, 5, 8 and 15 of Cycle 1; Days 1 (predose, 29 minutes from infusion start) and 8 of Cycles 2 and beyond until the follow-up visit (4 weeks after the last infusion)
Reported as:
Mean · mL/kg
Pharmacokinetic Measurement of Steady-State Volume of Distribution (Vss)
mL/kgrhuMAb 2C4: 2 mg/kgrhuMAb 2C4: 5 mg/kgrhuMAb 2C4: 10 mg/kgrhuMAb 2C4: 15 mg/kg
Pharmacokinetic Measurement of Steady-State Volume of Distribution (Vss)69.5 ± 13.774.1 ± 30.473.4 ± 13.685.3 ± 36.7
SecondaryPharmacokinetic Measurement of Initial Distribution Half-Life (t1/2 Initial)

A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.

Time frame:
Days 1 (predose, 89 minutes from infusion start, at 1.5, 4, and 8 hours postdose), 2, 5, 8 and 15 of Cycle 1; Days 1 (predose, 29 minutes from infusion start) and 8 of Cycles 2 and beyond until the follow-up visit (4 weeks after the last infusion)
Reported as:
Mean · days
Pharmacokinetic Measurement of Initial Distribution Half-Life (t1/2 Initial)
daysrhuMAb 2C4: 2 mg/kgrhuMAb 2C4: 5 mg/kgrhuMAb 2C4: 10 mg/kgrhuMAb 2C4: 15 mg/kg
Pharmacokinetic Measurement of Initial Distribution Half-Life (t1/2 Initial)0.96 ± 0.991.09 ± 0.741.23 ± 0.901.50 ± 1.17
SecondaryPharmacokinetic Measurement of Terminal Half-Life (t1/2 Terminal) in Days

A one-compartment model was used for the 0.5 mg/kg dose group, and a two-compartment model was used for the 2-15 mg/kg dose groups.

Time frame:
Days 1 (predose, 89 minutes from infusion start, at 1.5, 4, and 8 hours postdose), 2, 5, 8 and 15 of Cycle 1; Days 1 (predose, 29 minutes from infusion start) and 8 of Cycles 2 and beyond until the follow-up visit (4 weeks after the last infusion)
Reported as:
Mean · days
Pharmacokinetic Measurement of Terminal Half-Life (t1/2 Terminal) in Days
daysrhuMAb 2C4: 0.5 mg/kgrhuMAb 2C4: 2 mg/kgrhuMAb 2C4: 5 mg/kgrhuMAb 2C4: 10 mg/kgrhuMAb 2C4: 15 mg/kg
Pharmacokinetic Measurement of Terminal Half-Life (t1/2 Terminal) in Days2.6 ± 0.914.9 ± 1.117.2 ± 10.322.3 ± 9.918.6 ± 8.8

Adverse events

Collected over From baseline through 4 weeks after the last infusion of study drug, up to 56 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
rhuMAb 2C4: 0.5 mg/kg—3/3 (100%)3/3 (100%)
rhuMAb 2C4: 2 mg/kg—1/3 (33.3%)3/3 (100%)
rhuMAb 2C4: 5 mg/kg—2/4 (50%)4/4 (100%)
rhuMAb 2C4: 10 mg/kg—0/3 (0%)3/3 (100%)
rhuMAb 2C4: 15 mg/kg—5/8 (62.5%)8/8 (100%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventrhuMAb 2C4: 0.5 mg/kgrhuMAb 2C4: 2 mg/kgrhuMAb 2C4: 5 mg/kgrhuMAb 2C4: 10 mg/kgrhuMAb 2C4: 15 mg/kg
Pleural effusionRespiratory, thoracic and mediastinal disorders1/30/30/40/31/8
Pleuritic painRespiratory, thoracic and mediastinal disorders1/30/30/40/30/8
Supraventricular tachycardiaCardiac disorders0/31/30/40/30/8
Breast cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/30/30/40/30/8
Ureteric stenosisRenal and urinary disorders1/30/30/40/30/8
Jugular vein thrombosisVascular disorders1/30/30/40/30/8
DepressionPsychiatric disorders0/30/31/40/30/8
Mental status changesPsychiatric disorders0/30/31/40/30/8
Abdominal painGastrointestinal disorders0/30/30/40/31/8
DiarrhoeaGastrointestinal disorders0/30/30/40/31/8
Most frequent other events
Showing 10 of 153
Most frequent other events
EventrhuMAb 2C4: 0.5 mg/kgrhuMAb 2C4: 2 mg/kgrhuMAb 2C4: 5 mg/kgrhuMAb 2C4: 10 mg/kgrhuMAb 2C4: 15 mg/kg
VomitingGastrointestinal disorders3/31/34/40/33/8
NauseaGastrointestinal disorders3/31/32/42/32/8
FatigueGeneral disorders3/31/31/41/35/8
ConstipationGastrointestinal disorders2/30/31/40/32/8
Dry mouthGastrointestinal disorders1/30/30/42/30/8
PyrexiaGeneral disorders2/31/31/40/32/8
Oedema peripheralGeneral disorders2/30/30/40/32/8
HyperglycaemiaMetabolism and nutrition disorders2/30/30/41/31/8
HypernatremiaMetabolism and nutrition disorders0/30/30/42/30/8
RashSkin and subcutaneous tissue disorders0/32/31/42/31/8

Baseline characteristics

The baseline analysis population included all participants that were enrolled into one of the 5 treatment groups.

Age, Continuous
Age, Continuous(years)rhuMAb 2C4: 0.5 mg/kgrhuMAb 2C4: 2 mg/kgrhuMAb 2C4: 5 mg/kgrhuMAb 2C4: 10 mg/kgrhuMAb 2C4: 15 mg/kgTotal
Mean58 ± 20.455 ± 13.648 ± 13.861 ± 17.160 ± 8.256.7 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)rhuMAb 2C4: 0.5 mg/kgrhuMAb 2C4: 2 mg/kgrhuMAb 2C4: 5 mg/kgrhuMAb 2C4: 10 mg/kgrhuMAb 2C4: 15 mg/kgTotal
Female2130612
Male121329
08

Study locations

1 site
  • Cedars-Sinai Medical Center
    Los Angeles, California 90211, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2001, a primary completion of Aug 2003 and a completion of Aug 2003. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2015, 11 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2001
First posted
Nov 16, 2001
Start
Nov 2001
Primary completionActual
Aug 2003
CompletionActual
Aug 2003
Results first posted
Jul 27, 2015
Last update
Jul 27, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00027027
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Nov 16, 2001
Start date
Nov 2001
Primary completion
Aug 2003
Completion
Aug 2003
Results posted
Jul 27, 2015
Last update
Jul 27, 2015
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pertuzumab

Start the discussion